NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free KOD Stock Alerts $5.67 -0.19 (-3.24%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.58▼$6.0050-Day Range$3.07▼$6.3252-Week Range$1.37▼$9.80Volume903,796 shsAverage Volume591,710 shsMarket Capitalization$297.50 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kodiak Sciences alerts: Email Address Kodiak Sciences MarketRank™ Stock AnalysisAnalyst RatingReduce1.83 Rating ScoreUpside/Downside19.0% Upside$6.75 Price TargetShort InterestHealthy3.76% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.80) to ($3.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.92 out of 5 starsMedical Sector251st out of 946 stocksBiological Products, Except Diagnostic Industry33rd out of 160 stocks 1.9 Analyst's Opinion Consensus RatingKodiak Sciences has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on 1 buy rating, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.75, Kodiak Sciences has a forecasted upside of 19.0% from its current price of $5.67.Amount of Analyst CoverageKodiak Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.76% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kodiak Sciences has recently increased by 2.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKodiak Sciences has received a 73.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Kodiak Sciences is -0.87. Previous Next 2.6 News and Social Media Coverage News SentimentKodiak Sciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.Search InterestOnly 6 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders45.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.99% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kodiak Sciences are expected to grow in the coming year, from ($4.80) to ($3.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Kodiak Sciences Stock (NASDAQ:KOD)Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Read More KOD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KOD Stock News HeadlinesFebruary 24, 2024 | msn.comState of Texas: Ruling sparks Paxton’s push to oust conservative judges on Court of Criminal AppealsFebruary 23, 2024 | msn.comAgency asks public to name, get to know member of highly endangered Alaska whale populationMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 16, 2024 | finance.yahoo.comKOD Mar 2024 3.500 callFebruary 12, 2024 | finance.yahoo.comFollowing a 25% decline over last year, recent gains may please Kodiak Sciences Inc. (NASDAQ:KOD) institutional ownersFebruary 10, 2024 | usatoday.comA female stingray at a NC aquarium becomes pregnant without a male mate. But how?February 6, 2024 | bbc.comThe moment Jennifer Crumbley reacts to guilty verdictFebruary 6, 2024 | bbc.comDrone video shows graffiti covering luxury high-rise in LAMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 6, 2024 | msn.comHot water failures, grease buildup: See January's Centre County restaurant inspectionsFebruary 4, 2024 | bbc.comTaylor Swift/ Travis Kelce romance reaches White HouseFebruary 4, 2024 | msn.comYes, Colorado celebrates a frozen dead guy every year – here’s whyFebruary 3, 2024 | msn.comWatch: Alaska-native bears found wandering loose in FloridaFebruary 3, 2024 | bbc.comScene after small plane crashes into mobile homeFebruary 3, 2024 | bbc.comBiden attends transfer of US soldiers killed in JordanFebruary 1, 2024 | uk.news.yahoo.comDolphin Rescued After Getting Tangled in Crab Pot LineFebruary 1, 2024 | ca.news.yahoo.comN.L. Power rates could jump beyond projected 5.5 per cent in 2025, says PUBFebruary 1, 2024 | sg.news.yahoo.comOld lifeboat station to become seal rescue centreFebruary 1, 2024 | au.news.yahoo.comWatch: Alaska officials trigger ‘controlled’ avalanches to combat snow hazardsFebruary 1, 2024 | ca.news.yahoo.comNocturnal creature with bushy tail caught in a trap in Madagascar. It’s a new speciesFebruary 1, 2024 | au.news.yahoo.comQ & A: Veteran councillor says another, better single-use items bylaw will comeFebruary 1, 2024 | ca.style.yahoo.comBears native to Alaska found wandering roadside in FloridaFebruary 1, 2024 | au.lifestyle.yahoo.comOrbital Composites and Virtus Solis team up for space-based solar power missionFebruary 1, 2024 | msn.comBiogen (BIIB) to Stop Selling Alzheimer's Disease Drug AduhelmJanuary 31, 2024 | uk.news.yahoo.comFirst of back-to-back atmospheric rivers pushes into California. Officials urge storm preparationsJanuary 31, 2024 | news.yahoo.comTwo bears unique to Alaska found wandering Florida Panhandle. How did they get there?January 31, 2024 | yahoo.comVIDEO: 2 Alaska-native bears found walking on side of Florida roadSee More Headlines Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/18/2024Next Earnings (Estimated)3/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KOD CUSIPN/A CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$6.75 High Stock Price Target$12.00 Low Stock Price Target$2.00 Potential Upside/Downside+19.0%Consensus RatingReduce Rating Score (0-4)1.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-333,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.87% Return on Assets-44.42% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.34 per share Price / Book0.68Miscellaneous Outstanding Shares52,470,000Free Float28,650,000Market Cap$297.50 million OptionableOptionable Beta2.17 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Victor Perlroth M.D. (Age 51)Co-Founder, Chairman, CEO & President Comp: $1.08MMr. John A. Borgeson CPA (Age 62)M.B.A., Senior VP, CFO & Secretary Comp: $667.52kDr. Michael S. Louie Ph.D.Senior VP of Digital Transformation & Chief Information OfficerDr. Hong Liang (Age 52)Senior Vice President of Discovery Medicine Comp: $300.71kDr. Stephen Raillard Ph.D.Senior Vice President of Chemical Development & ManufacturingMs. Almas Qudrat M.Sc.Senior Vice President of Quality OperationsDr. J. Pablo Velazquez-Martin M.D.Senior VP of Clinical Research & DevelopmentTracy ChienVP & Corporate ControllerMore ExecutivesKey CompetitorsPoseida TherapeuticsNASDAQ:PSTXAura BiosciencesNASDAQ:AURAMonte Rosa TherapeuticsNASDAQ:GLUESOPHiA GENETICSNASDAQ:SOPHTScan TherapeuticsNASDAQ:TCRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 10,454 shares on 3/11/2024Ownership: 3.132%Goldman Sachs Group Inc.Sold 41,573 shares on 3/1/2024Ownership: 0.750%Vanguard Group Inc.Bought 10,454 shares on 2/15/2024Ownership: 3.132%Nuveen Asset Management LLCBought 3,769 shares on 2/15/2024Ownership: 0.277%Citadel Advisors LLCSold 4,000 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KOD Stock Analysis - Frequently Asked Questions Should I buy or sell Kodiak Sciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" KOD shares. View KOD analyst ratings or view top-rated stocks. What is Kodiak Sciences' stock price target for 2024? 6 brokerages have issued 1-year price targets for Kodiak Sciences' stock. Their KOD share price targets range from $2.00 to $12.00. On average, they expect the company's share price to reach $6.75 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for KOD or view top-rated stocks among Wall Street analysts. How have KOD shares performed in 2024? Kodiak Sciences' stock was trading at $3.04 on January 1st, 2024. Since then, KOD shares have increased by 86.5% and is now trading at $5.67. View the best growth stocks for 2024 here. When is Kodiak Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our KOD earnings forecast. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) announced its earnings results on Tuesday, November, 9th. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.14. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did Kodiak Sciences IPO? (KOD) raised $126 million in an IPO on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Kodiak Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Newtyn Management LLC (3.38%), Vanguard Group Inc. (3.13%), Vanguard Group Inc. (3.13%), Dimensional Fund Advisors LP (0.83%), Goldman Sachs Group Inc. (0.75%) and Goldman Sachs Group Inc. (0.75%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich, John A Borgeson and Victor Perlroth. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KOD) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBitcoin dollar warningStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.